Cargando…
TAVR: nemesis of NOACs?
Data on non-vitamin K antagonist oral anticoagulants (NOACs) in transcatheter aortic valve replacement (TAVR) patients are controversial. In patients without atrial fibrillation (AF), rivaroxaban showed enhanced ischemia and bleeding as compared to standard of care. ENVISAGE showed enhanced bleeding...
Autores principales: | Polzin, Amin, Helten, Carolin, Metzen, Daniel, Zako, Saif, Veulemans, Verena, Kelm, Malte, Zeus, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925602/ https://www.ncbi.nlm.nih.gov/pubmed/36318378 http://dx.doi.org/10.1007/s11239-022-02721-6 |
Ejemplares similares
-
Incidence and Risk Assessment of Infolding Using Self-Expandable Devices in TAVR
por: Veulemans, Verena, et al.
Publicado: (2022) -
Factors associated with a high or low implantation of self-expanding devices in TAVR
por: Veulemans, Verena, et al.
Publicado: (2021) -
Predictors of calcification distribution in severe tricuspid aortic valve stenosis
por: Piayda, Kerstin, et al.
Publicado: (2021) -
Short- and Mid-Term Outcomes in Patients Deemed Inoperable Undergoing Transapical and Transfemoral TAVR with an STS-PROM below Four Percent
por: Veulemans, Verena, et al.
Publicado: (2021) -
Excess Mortality in Aspirin and Dipyrone (Metamizole) Co‐Medicated in Patients With Cardiovascular Disease: A Nationwide Study
por: Polzin, Amin, et al.
Publicado: (2021)